Genome Mapping Could End Disease; Special Report by Leading Financial Web Site Penny Stock Detectives

In a recent Penny Stock Detectives article, editor Danny Esposito points out that when the map of the human genome was first revealed.

New York, NY (prHWY.com) August 4, 2012 - In a recent Penny Stock Detectives article, editor Danny Esposito points out that when the map of the human genome was first revealed, everyone knew it would revolutionize treatments for diseases. Esposito notes that it comes as no surprise that researchers are now able to take the human genome project to the individual level.
"With a small sample of DNA, researchers can create each person's unique complete genome sequencing," reports Esposito. "While researchers have been moving toward this goal for some time, the problems before stemmed from the fact that to understand where a person's problem genes went wrong, they would need to conduct tests on the parents to have a complete picture."
The new mapping method no longer requires this step, which saves time and money and, in the future, may allow biotech companies and big pharma to get the complete picture from just the individual, comments Esposito.
According to Esposito, what biotech companies want to isolate are those malfunctioning genes that are hereditary and lead to disease.
"This would be the ultimate preventative medicine where a malfunctioning gene can be altered at a young age and prevent a disease from developing," observes Esposito.
The cost of creating the complete human genome picture of each individual is still a little expensive, but biotech companies are using new technological innovations in the hopes of significantly reducing that cost, reports Esposito. According to him, this would mean that in the future, every person who wants a complete map of themselves and those people whose families have histories of hereditary diseases could use this procedure to prevent a lot of pain and suffering, hopefully extending their lives.
It is easier to provide an example of how gene therapy can work in fighting a disease, which can be viewed in the broader context of repairing the damage in each individual's genome, suggests Esposito.
Spinal muscular atrophy is a rare disease that takes the lives of very young children, for which there is currently no cure, explain Esposito. After studying the genome of infants with the disease, researchers have discovered that there is a gene missing that sends important signals to the spine to allow it to function properly, he reports.
The Penny Stock Detectives editor also notes that in an experiment with mice, when a properly functioning gene was introduced to a mouse with spinal muscular atrophy, the mouse's life was extended. Esposito acknowledges this could be the possible cure biotech companies were looking for, but says these exciting initial results need to be tested in people next, in the hopes it will cure this terrible disease.
"The human genome project will have ramifications for medicine for decades to come," argues Esposito. "Being able to map our own unique genome and repair any malfunctioning genes would be an incredible accomplishment. The first steps toward this goal have been taken and more importantly, have been successful."
To see the full article and to learn more about Penny Stock Detectives, visit www.pennystockdetectives.com.

The editors of Penny Stock Detectives believe low-priced stocks, when researched properly, present investors with great opportunities to accumulate wealth and to increase the value of their investment portfolios. You can learn more about Penny Stock Detectives at www.pennystockdetectives.com.

###

Tag Words: biotech companies, big pharma

Categories: Business

Press Release Contact
350 5th Avenue, 59th Floor New York, NY 10118

Link To This Press Release:

URL HTML Code